CEO and President
Kevin Honeycutt joined Alliance for Cancer Gene Therapy (ACGT) as its new CEO and President in December 2018. Most recently, he was the President and CEO of the Avon Breast Cancer Crusade (ABCC) since 2015. At ACGT, Mr. Honeycutt’s principal role is to enhance the vision of ACGT, begun in 2001 by its co-founders Barbara Netter and her late husband Edward, and to spearhead ACGT’s current focus on funding the next generation of challenges brought by metastatic cancers and solid tumors and to continue to build ACGT’s alliances and joint ventures.
Prior to ABCC, Mr. Honeycutt served as Executive Director of the Avon Foundation for Women for five years, and in a variety of consulting roles through his firm Honeycutt Partners, including projects for, among others, the American Diabetes Association, DaVita, Inc./The Kidney Trust, the Entertainment Industry Foundation and the San Francisco AIDS Foundation.
Mr. Honeycutt serves on the Board of Directors of the Global Cancer Institute and Friends of Mozart. He is a past Board member of the UCLA Jonsson Cancer Center Foundation.Return to Leadership